Quantitative metric for assessment of pancreatic ductal adenocarcinoma treatment response in T1-weighted gadolinium-enhanced magnetic resonance imaging.

ABSTRACT:

Background

We theoretically derived a new quantitative metric reflecting the product of T1 signal intensity and contrast media concentration (T1C) using first principles for the signal provided by the gradient echo sequence. This metric can be used with conventional gadolinium contrast-enhanced magnetic resonance imaging (CE-MRI) exams. We used this metric to test our hypothesis that gadolinium enhancement changes with pancreatic ductal adenocarcinoma (PDA) treatment response, and that this metric may differentiate responders from non-responders.

Methods

Out of 264 initially identified patients, a final total of 35 patients with PDA were included in a retrospective study of responders (n=24) and non-responders (n=11), which used changes in cancer antigen 19-9 (CA 19-9

SUBMITTER: Liau J 

PROVIDER: S-EPMC7755136 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature